Haemonetics Corporation HAE
Regular-session close
After hours · Nov 20, 5:31 PM ET
- YTD
- +49.92%
- 1 year
- +59.96%
5D -3.02 (-2.45%)
- Market cap
- 5.47B
- Revenue (ttm)
- 1.38B
- Profit margin
- 7.52%
- EPS (ttm)
- 2.26
- Shares out
- 45.54M
- P/E ratio
- 53.17
- Forward P/E
- 19.16
- YTD return
- +49.92%
- 1-year return
- +59.96%
- 50-day average
- 114.82
- Volume
- 382.96K
- Avg volume
- 662.81K
- Open
- 120.37
- Previous close
- 120.37
- Day's range
- 119.68 – 122.00
- 52-week range
- 52.24 – 127.42
- Beta
- 0.59
- Analysts
- Buy
- Price target
- 147.18 (+22.5%)
- Earnings date
- Feb 4, 2027
Key statistics
- 200-day average
- 82.37
- Enterprise value
- 6.34B
- PEG ratio
- 1.92
- Price / sales
- 3.96
- Price / book
- 6.09
- Revenue growth
- 9.30%
- Free cash flow
- 297.44M
- Total cash
- 262.91M
- Total debt
- 1.12B
- Return on equity
- 11.89%
- Short % of float
- 9.25%
Fundamental scorecard
11 of 25 checks passed on HAE’s reported financials
11of 25 checks passed
- Value 1 of 5
- Growth 4 of 5
- Profitability 3 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 26, 2026.
Analyst view
Consensus: buy
- Target (low)
- 125.00
- Target (mean)
- 147.18
- Target (high)
- 165.00
- Strong buy4
- Buy6
- Hold2
- Sell0
- Strong sell0
Next earnings
Feb 4, 2027
Expected Feb 4, 2027. Consensus EPS estimate 1.26.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 4, 2027 | Dec 26, 2026 | 1.26 | — | — | — |
| Nov 5, 2026 | Sep 26, 2026 | 1.29 | 1.35 | +0.06 | +4.65% |
| Aug 6, 2026 | Jun 27, 2026 | 1.08 | 1.14 | +0.06 | +5.56% |
| May 7, 2026 | Mar 28, 2026 | 1.28 | 1.29 | +0.01 | +0.78% |
| Feb 5, 2026 | Dec 27, 2025 | 1.27 | 1.31 | +0.04 | +3.15% |
| Nov 6, 2025 | Sep 27, 2025 | 1.12 | 1.27 | +0.15 | +13.39% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 16, 2026 | Citizens | main | Market Outperform | Market Outperform |
| Nov 13, 2026 | Jefferies | init | — | Buy |
| Nov 6, 2026 | Citigroup | main | Buy | Buy |
| Nov 6, 2026 | Barrington Research | main | Outperform | Outperform |
| Nov 5, 2026 | BTIG | main | Buy | Buy |
| Oct 9, 2026 | Barrington Research | main | Outperform | Outperform |
About Haemonetics Corporation
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- haemonetics.com
News
Pharvaris: Orally Available HAE Therapy Appears To Be Ideal All Court Player
BioCryst Pharmaceuticals Sees Revenue Near Top of Guidance as It Expands HAE Portfolio
Haemonetics Announces CE Mark Certification for the VASCADE MVP® XL Venous Vascular Closure System Citizens Maintains Market Outperform on Haemonetics, Raises Price Target to $144
This Analog Devices Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Jefferies Initiates Coverage On Haemonetics with Buy Rating, Announces Price Target of $150
Citigroup Maintains Buy on Haemonetics, Raises Price Target to $149
Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $145
BTIG Maintains Buy on Haemonetics, Raises Price Target to $142
Haemonetics Q2 2027 Earnings Call Transcript
Your note
Sign in to keep a note on HAE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ABERNATHY ROBERT E | Director | Stock Award(Grant) | Jul 23, 2026 | 27,519 |
| BASIL MICHELLE L | General Counsel | Stock Award(Grant) | May 14, 2026 | 68,829 |
| DARECCA JAMES | Chief Financial Officer | Stock Award(Grant) | May 14, 2026 | 54,444 |
| DOCKENDORFF CHARLES J | Director | Stock Award(Grant) | Jul 23, 2025 | 25,041 |
| GALVIN ROY | Officer | Stock Award(Grant) | May 14, 2026 | 39,882 |
| KROLL MARK W | Director | Stock Award(Grant) | Jul 23, 2026 | 27,295 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 13.07% | 5,953,537 | 715.02M | Sep 29, 2026 |
| Neuberger Berman Group, LLC | 7.65% | 3,481,774 | 418.16M | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 5.49% | 2,501,221 | 300.40M | Sep 29, 2026 |
| Ariel Investments, LLC | 4.77% | 2,173,575 | 261.05M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 4.49% | 2,045,810 | 245.70M | Sep 29, 2026 |
| AQR Capital Management, LLC | 4.00% | 1,822,616 | 218.90M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.56% | 1,621,301 | 194.72M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.17% | 1,441,654 | 173.14M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.62% | 1,194,166 | 143.42M | Sep 29, 2026 |
| NEUBERGER BERMAN EQUITY FUNDS-Neuberger Genesis Fund | 2.59% | 1,179,168 | 141.62M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.29% | 1,041,356 | 125.07M | Jun 29, 2026 |
| Touchstone Strategic TRT-Touchstone Strategic TRT-Touchstone Small Com | 1.35% | 614,824 | 73.84M | Jun 29, 2026 |
